Treatment of Recurrent or Metastatic Uterine Adenosarcoma
Sarcoma · 2017 · 2017 · 1-9
DOI: 10.1155/2017/4680273 ↗Kurz gefasst
Fachartikel in der Zeitschrift Sarcoma, 2017. Verfasst von Michael J Nathenson und 4 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA 02215, USA. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: WWWW Foundation, Inc., Amschwand Sarcoma Cancer Foundation.
Abstract (Originalsprache)
Purpose
This study retrospectively evaluated overall survival (OS) by treatment of recurrent or metastatic uterine adenosarcoma including surgery, radiation, chemotherapy, and hormonal therapy and evaluated OS and progression-free survival (PFS) after 1st line systemic chemotherapy.
Methods
78 patients with recurrent or metastatic adenosarcoma comprised the study population. The Kaplan-Meier method was used to estimate OS and PFS. The log-rank test was performed to test the difference in survival between groups.
Results
Median OS from diagnosis of recurrent or metastatic disease was 1.8 yrs. OS was influenced by pathology on recurrence, p =0 .035 . Median OS differed by surgery for 1st recurrence 26.3 months versus 15.1 months. OS was not influenced by chemotherapy, p =0 .58 , palliative radiation, p =0 .58 , or hormonal therapy, p =0 .15 . The response rate (CR + PR) per RECIST 1.1 for chemotherapy was 31.2% for doxorubicin-based regimens and 14.3% for gemcitabine/docetaxel. OS since 1st line chemotherapy was not significantly different among chemotherapy regimens. However, the median PFS was superior for doxorubicin/ifosfamide (15.4 months) compared to gemcitabine/docetaxel (5.0 months), platinum-based regimens (5.7 mo), or other doxorubicin-based regimens (6.5 months).
Conclusion
These results suggest that surgery is an important treatment modality for recurrent or metastatic uterine adenosarcoma, and the most effective chemotherapeutics are doxorubicin/ifosfamide and gemcitabine/docetaxel.
Autor:innen und Institutionen
- Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA 02215, USA.
- Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd Unit 450, Houston, TX 77030, USA.
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd Unit 450, Houston, TX 77030, USA.
- Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd Unit 450, Houston, TX 77030, USA.
ORCID-Profile: Michael J Nathenson
Förderung
- WWWW Foundation, Inc.
- Amschwand Sarcoma Cancer Foundation
Zitieren
APA
Nathenson, M. J., Conley, A. P., Lin, H., Fleming, N., & Ravi, V. (2017). Treatment of Recurrent or Metastatic Uterine Adenosarcoma. Sarcoma, 2017, 1-9. https://doi.org/10.1155/2017/4680273
Vancouver
Nathenson MJ, Conley AP, Lin H, Fleming N, Ravi V. Treatment of Recurrent or Metastatic Uterine Adenosarcoma. Sarcoma. 2017;2017:1-9. doi:10.1155/2017/4680273
BibTeX
@article{Nathenson2017,
author = {Nathenson, Michael J and Conley, Anthony P and Lin, Heather and Fleming, Nicole and Ravi, Vinod},
title = {Treatment of Recurrent or Metastatic Uterine Adenosarcoma},
journal = {Sarcoma},
year = {2017},
volume = {2017},
pages = {1--9},
doi = {10.1155/2017/4680273}
}
EUVIMED